Our results led us to the observation that TERT promoter mutation was associated with the MGMT methylation benefit in GBM patients treated by TMZ whereas, in the TERT-wt group, MGMT methylation was not associated with improved OS in these patients. Here, MGMT is linked to glioblastoma.